TI
SUPN icon

Trexquant Investment’s Supernus Pharmaceuticals SUPN Stock Holding History

Trexquant Investment’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-31,233
Closed -$984K – 1902
2025
Q2 		$984K Sell
31,233
-113,261
-78% -$3.63M 0.01% 1109
2025
Q1 		$4.73M Buy
144,494
+70,219
+95% +$2.49M 0.06% 529
2024
Q4 		$2.69M Sell
74,275
-20,677
-22% -$728K 0.03% 757
2024
Q3 		$2.96M Buy
+94,952
New +$2.96M 0.04% 665
2024
Q1 		– Sell
-18,122
Closed -$524K – 1774
2023
Q4 		$524K Sell
18,122
-11,887
-40% -$315K 0.01% 1068
2023
Q3 		$827K Buy
30,009
+17,390
+138% +$529K 0.02% 827
2023
Q2 		$379K Sell
12,619
-33,896
-73% -$1.19M 0.01% 1108
2023
Q1 		$1.69M Buy
46,515
+22,855
+97% +$879K 0.05% 518
2022
Q4 		$844K Buy
+23,660
New +$822K 0.02% 708
2021
Q3 		– Sell
-12,054
Closed -$371K – 1473
2021
Q2 		$371K Buy
+12,054
New +$370K 0.03% 618
2021
Q1 		– Sell
-10,650
Closed -$268K – 1450
2020
Q4 		$268K Buy
+10,650
New +$229K 0.03% 758
2020
Q1 		– Sell
-10,832
Closed -$257K – 1405
2019
Q4 		$257K Buy
+10,832
New +$263K 0.02% 813
2019
Q2 		– Sell
-82,901
Closed -$2.9M – 1105
2019
Q1 		$2.9M Buy
82,901
+21,524
+35% +$801K 0.21% 137
2018
Q4 		$2.04M Buy
+61,377
New +$2.64M 0.13% 235
2018
Q1 		– Sell
-14,392
Closed -$574K – 1363
2017
Q4 		$574K Buy
+14,392
New +$569K 0.06% 466
2017
Q1 		– Sell
-22,000
Closed -$556K – 1324
2016
Q4 		$556K Buy
+22,000
New +$492K 0.09% 390
2016
Q2 		– Sell
-67,382
Closed -$1.03M – 1089
2016
Q1 		$1.03M Buy
67,382
+12,567
+23% +$164K 0.12% 288
2015
Q4 		$737K Buy
+54,815
New +$848K 0.06% 521
2015
Q2 		– Sell
-59,000
Closed -$713K – 1228
2015
Q1 		$713K Buy
+59,000
New +$557K 0.07% 530

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Trexquant Investment's SUPN Position: Q3 2025 in Review

Trexquant Investment sold out of Supernus Pharmaceuticals (SUPN) in Q3 2025, closing a stake of 31,233 shares — an estimated $984K sold.

Trexquant Investment first reported a position in SUPN in Q1 2015 and held it in 19 quarters. The position peaked at $4.73M in Q1 2025. 310 funds tracked by Wall St. Rank hold SUPN as of Q3 2025.

  • Trexquant Investment reported no remaining Supernus Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Trexquant Investment sold 31,233 Supernus Pharmaceuticals shares in Q3 2025, an estimated $984K.
  • Trexquant Investment first reported a position in Supernus Pharmaceuticals in Q1 2015 and held it in 19 quarters.
  • Trexquant Investment's Supernus Pharmaceuticals position peaked at $4.73M in Q1 2025.
  • 310 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2025.

Based on Trexquant Investment's 13F filing for Q3 2025, filed 14 Nov 2025.